Literature DB >> 20846711

Correlation between serum prostate-specific antigen and cancer volume in prostate glands of different sizes.

Gustavo F Carvalhal1, Saima N Daudi, Donghui Kan, Dana Mondo, Kimberly A Roehl, Stacy Loeb, William J Catalona.   

Abstract

OBJECTIVES: To further evaluate the relationship of prostate-specific antigen (PSA) with prostate size and tumor volume in a contemporary surgical series. Although early studies showed a strong correlation between PSA and tumor volume, it has been suggested that PSA is no longer a valid marker for prostate cancer and only correlates with prostate size.
METHODS: From 2003 to 2009, 1234 men with data on prostate weight and total tumor volume underwent radical prostatectomy by a single surgeon. Prostate size was classified into tertiles: small (≤ 41.2 g), medium (41.3-54.5 g), and large (≥ 54.6 g). Pearson correlation coefficients were used to examine the relationship of PSA with prostate size and tumor volume across different prostate sizes.
RESULTS: Median preoperative PSA was 4.9 ng/mL (standard deviation ± 4.6), mean prostate size was 51.7 g, and mean tumor volume was 5.6 cm(3). PSA had a significant correlation with prostate size only at a prostate weight ≥ 54.6 g (P = .02). Regardless of prostate size, PSA had a more robust significant correlation with tumor volume than with prostate size (all P < .0001).
CONCLUSIONS: PSA was significantly correlated with prostate size only in the largest prostate glands, but was significantly associated with tumor volume in small, medium, or large prostates. Thus, PSA continues to be a better marker for tumor volume than for prostate size.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20846711      PMCID: PMC2975771          DOI: 10.1016/j.urology.2009.11.056

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  28 in total

1.  Updated protocol for the examination of specimens from patients with carcinomas of the prostate gland: a basis for checklists. Cancer Committee.

Authors:  J R Srigley; M B Amin; D G Bostwick; D J Grignon; M E Hammond
Journal:  Arch Pathol Lab Med       Date:  2000-07       Impact factor: 5.534

2.  Preoperative serum prostate-specific antigen (PSA) below 10 microg/l predicts neither the presence of prostate cancer nor the rate of postoperative PSA failure.

Authors:  T A Stamey
Journal:  Clin Chem       Date:  2001-04       Impact factor: 8.327

3.  Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients.

Authors:  T A Stamey; J N Kabalin; J E McNeal; I M Johnstone; F Freiha; E A Redwine; N Yang
Journal:  J Urol       Date:  1989-05       Impact factor: 7.450

4.  Visual estimate of the percentage of carcinoma is an independent predictor of prostate carcinoma recurrence after radical prostatectomy.

Authors:  G F Carvalhal; P A Humphrey; P Thorson; Y Yan; C G Ramos; W J Catalona
Journal:  Cancer       Date:  2000-09-15       Impact factor: 6.860

5.  Assessment of morphometric measurements of prostate carcinoma volume.

Authors:  M Noguchi; T A Stamey; J E McNeal; C E Yemoto
Journal:  Cancer       Date:  2000-09-01       Impact factor: 6.860

6.  Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy.

Authors:  Anthony V D'Amico; Ming-Hui Chen; Kimberly A Roehl; William J Catalona
Journal:  N Engl J Med       Date:  2004-07-08       Impact factor: 91.245

7.  The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?

Authors:  Thomas A Stamey; Mitchell Caldwell; John E McNeal; Rosalie Nolley; Marci Hemenez; Joshua Downs
Journal:  J Urol       Date:  2004-10       Impact factor: 7.450

8.  Prostate-specific antigen cutoff of 2.6 ng/mL for prostate cancer screening is associated with favorable pathologic tumor features.

Authors:  Jason S Krumholtz; Gustavo F Carvalhal; Christian G Ramos; Deborah S Smith; Phataraporn Thorson; Yan Yan; Peter A Humphrey; Kimberly A Roehl; William J Catalona
Journal:  Urology       Date:  2002-09       Impact factor: 2.649

9.  Cancer statistics, 2009.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2009-05-27       Impact factor: 508.702

10.  Prognostic significance of tumor volume after radical prostatectomy: a multivariate analysis of pathological prognostic factors.

Authors:  Laurent Salomon; Olivier Levrel; Aristotelis G Anastasiadis; Jacques Irani; Alexandre De La Taille; Fabien Saint; Dimitri Vordos; Antony Cicco; Andras Hoznek; Dominique Chopin; Claude Clément Abbou
Journal:  Eur Urol       Date:  2003-01       Impact factor: 20.096

View more
  20 in total

1.  Does the prostate volume always effect cancer detection rate in prostate biopsy? Additional role of prostate-specific antigen levels: A retrospective analysis of 2079 patients.

Authors:  Engin Kandıralı; Mustafa Zafer Temiz; Aykut Çolakerol; Emrah Yürük; Atilla Semerciöz; Ahmet Yaser Müslümanoğlu
Journal:  Turk J Urol       Date:  2018-03-16

2.  The influence of PSA flare in mCRPC patients treated with alpha-emitting radiopharmaceuticals.

Authors:  Francesco Ceci; Giulia Polverari; Jeremie Calais; Paolo Castellucci
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-12       Impact factor: 9.236

3.  Does salvage radiation therapy change the biology of recurrent prostate cancer based on PSA doubling times? Results from the SEARCH database.

Authors:  Roberto L Muller; Joseph C Presti; William J Aronson; Martha K Terris; Christopher J Kane; Christopher L Amling; Stephen J Freedland
Journal:  Urology       Date:  2012-03-23       Impact factor: 2.649

4.  PET/CT imaging for evaluating response to therapy in castration-resistant prostate cancer.

Authors:  Francesco Ceci; Paolo Castellucci; Cristina Nanni; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-11       Impact factor: 9.236

Review 5.  Therapy assessment in prostate cancer using choline and PSMA PET/CT.

Authors:  Francesco Ceci; Ken Herrmann; Boris Hadaschik; Paolo Castellucci; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-05-25       Impact factor: 9.236

6.  Functional analysis of single cells identifies a rare subset of circulating tumor cells with malignant traits.

Authors:  Xiaosai Yao; Atish D Choudhury; Yvonne J Yamanaka; Viktor A Adalsteinsson; Todd M Gierahn; Christina A Williamson; Carla R Lamb; Mary-Ellen Taplin; Mari Nakabayashi; Matthew S Chabot; Tiantian Li; Gwo-Shu M Lee; Jesse S Boehm; Philip W Kantoff; William C Hahn; K Dane Wittrup; J Christopher Love
Journal:  Integr Biol (Camb)       Date:  2014-02-13       Impact factor: 2.192

7.  Brachytherapy application with in situ dose painting administered by gold nanoparticle eluters.

Authors:  Neeharika Sinha; Gizem Cifter; Erno Sajo; Rajiv Kumar; Srinivas Sridhar; Paul L Nguyen; Robert A Cormack; G Mike Makrigiorgos; Wilfred Ngwa
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-12-05       Impact factor: 7.038

8.  A large, benign prostatic cyst presented with an extremely high serum prostate-specific antigen level.

Authors:  Han-Kuang Chen; Richard Pemberton
Journal:  BMJ Case Rep       Date:  2016-01-08

9.  Association Between Early PSA Increase and Clinical Outcome in Patients Treated with Enzalutamide for Metastatic Castration Resistant Prostate Cancer.

Authors:  Vincenza Conteduca; Simon J Crabb; Emanuela Scarpi; Catherine Hanna; Francesca Maines; Helen Joyce; Paolo Fabbri; Lisa Derosa; Francesco Massari; Cristian Lolli; Sunnya Zarif; Robert J Jones; Orazio Caffo; Tony Elliott; Ugo De Giorgi
Journal:  Mol Diagn Ther       Date:  2016-06       Impact factor: 4.074

10.  Does larger tumor volume explain the higher prostate specific antigen levels in black men with prostate cancer--Results from the SEARCH database.

Authors:  Zachary Klaassen; Lauren Howard; Martha K Terris; William J Aronson; Matthew R Cooperberg; Christopher L Amling; Christopher J Kane; Stephen J Freedland
Journal:  Cancer Epidemiol       Date:  2015-10-06       Impact factor: 2.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.